By Turna Ray
This article was originally posted on March 12.
A new boxed pharmacogenomics warning from the US Food and Drug Administration for the anti-platelet drug Plavix leaves doctors to make some difficult risk/benefit determinations about whether to genetically test their patients ahead of Plavix administration, or put them on another drug and risk different toxicities.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
